Table 2. Interventional data and cardiovascular drugs among groups stratified by door-to-balloon times .
| Door-to-balloon time (minutes) | < 45 | 45-90 | 91-135 | > 135 | p-value |
| Diagnostic cardiac angiography | |||||
| Cardiac angiography n (%) | 189 (100.0%) | 443 (100.0%) | 293 (98.0%) | 398 (99.3%) | < 0.01* |
| Median time to, hours | 0.5 (0.4-0.6) | 1.0 (0.8-1.2) | 1.6 (1.4-1.9) | 3.03 (2.4-4.9) | < 0.01* |
| Culprit artery territory, n (%) | |||||
| Left main | 11 (5.8%) | 7 (1.6%) | 4 (1.3%) | 3 (0.8%) | < 0.01* |
| Left artery disease | 115 (60.9%) | 230 (51.9%) | 152 (50.8%) | 209 (52.1%) | 0.14 |
| Left circumflex | 45 (23.8%) | 46 (10.4%) | 31 (10.4%) | 55 (13.7%) | < 0.01* |
| Right coronary artery | 97 (51.3%) | 185 (41.8%) | 120 (40.1%) | 156 (38.9%) | 0.03* |
| Culprit lesion stenosis | 95.5 ± 12.5 | 95.4 ± 12.1 | 96.0 ± 8.8 | 94.8 ± 11.2 | 0.55 |
| Initial coronary flow, n (%) | |||||
| TIMI 0/1 | 151 (84.8%) | 302 (71.6%) | 208 (72.2%) | 260 (69.0%) | < 0.01* |
| TIMI 2 | 13 (7.3%) | 73 (17.3%) | 39 (13.5%) | 72 (19.1%) | |
| TIMI 3 | 14 (7.9%) | 47 (11.1%) | 41 (14.2%) | 45 (11.9%) | |
| Unknown | 11 | 21 | 11 | 24 | |
| IABP | 85 (45.0%) | 82 (18.5%) | 53 (17.7%) | 92 (22.9%) | < 0.01* |
| Echocardiography, n (%) | |||||
| Normal | 91 (57.2%) | 221 (59.3%) | 149 (60.3%) | 206 (63.4%) | 0.42 |
| Mild LV systolic dysfunction | 52 (32.7%) | 104 (27.9%) | 72 (29.2%) | 78 (24.0%) | |
| Moderate LV systolic dysfunction | 14 (8.8%) | 35 (9.4%) | 18 (7.3%) | 35 (10.8%) | |
| Severe LV systolic dysfunction | 2 (1.3%) | 13 (3.5%) | 8 (3.2%) | 6 (1.9%) | |
| Median ejection fraction | 53.0 (47.0, 60.0) | 53.0 (46.0, 63.0) | 54.0 (46.0, 61.0) | 54.0 (46.0, 62.0) | 0.92 |
| PCI | |||||
| Median time to (minutes) | 31.0 (23.0-40.0) | 69.0 (58.0-79.0) | 111.0 (102.0-124.0) | 197.5 (160.0-308.0) | < 0.01* |
| Stent type, n (%) | |||||
| Bare-metal stents | 142 (78.9%) | 328 (75.6%) | 200 (68.3%) | 274 (71.0%) | 0.04* |
| Drug-eluting stents | 25 (13.9%) | 75 (17.3%) | 64 (21.8%) | 80 (20.7%) | |
| Both | 7 (3.9%) | 4 (0.9%) | 6 (2.1%) | 10 (2.6%) | |
| None | 6 (3.3%) | 27 (6.2%) | 23 (7.9%) | 22 (5.7%) | |
| Unknown | 3 | 4 | 5 | 6 | |
| Lesion successfully treated | 1.3 ± 0.6 | 1.2 ± 0.6 | 1.3 ± 0.6 | 1.3 ± 0.6 | 0.57 |
| Cardiovascular drugs | |||||
| DAPT, n (%) | |||||
| At discharge | 172 (91.0%) | 375 (84.7%) | 256 (85.6%) | 334 (83.3%) | 0.09 |
| At 6 months | 116 (72.1%) | 260 (65.0%) | 165 (62.5%) | 229 (64.7%) | 0.24 |
| At 12 months | 38 (25.3%) | 97 (25.9%) | 70 (29.2%) | 73 (22.3%) | 0.33 |
| Beta blockers, n (%) | |||||
| At discharge | 113 (59.8%) | 245 (55.4%) | 173 (57.9%) | 237 (59.1%) | 0.64 |
| At 6 months | 104 (64.6%) | 250 (62.5%) | 170 (64.4%) | 235 (66.4%) | 0.74 |
| At 12 months | 92 (61.3%) | 237 (63.2%) | 159 (66.3%) | 211 (64.5%) | 0.77 |
| ACEI/ARB, n (%) | |||||
| At discharge | 132 (69.8%) | 302 (68.2%) | 223 (74.6%) | 262 (65.3%) | 0.07 |
| At 6 months | 102 (63.4%) | 264 (66.0%) | 176 (66.7%) | 236 (66.7%) | 0.89 |
| At 12 months | 89 (59.3%) | 249 (66.4%) | 150 (62.5%) | 204 (62.4%) | 0.43 |
| Statin, n (%) | |||||
| At discharge | 124 (65.6%) | 280 (63.2%) | 207 (69.2%) | 264 (65.8%) | 0.41 |
| At 6 months | 100 (62.1%) | 266 (66.5%) | 188 (71.2%) | 225 (63.6%) | 0.15 |
| At 12 months | 101 (67.3%) | 246 (65.6%) | 165 (68.8%) | 189 (57.8%) | 0.03* |
CABG, coronary artery bypass grafting; CAG, coronary artery angiogram; IABP, intra-aortic balloon pump; LV, left ventricle; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in myocardial infarction.
* Comparison among groups by chi-square test for categorical variables and by ANOVA test for continuous variables.